Company ProfilePremium

Advanced Health Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Advanced Health Limited - Company showcase

Year Founded & Workforce

1997

Advanced Health Limited logo

Advanced Health Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Advanced Health Limited Overview

Advanced Health is a privately held South African operator of independent, same-day surgical hospitals (day hospitals). It runs a network of nine facilities in Gauteng, Mpumalanga, the Western Cape and the Eastern Cape. Its proposition is cost: the company says its same-day procedures are priced up to 30% below the same procedure in larger acute hospitals [S35]. It also targets the medical schemes, including low-cost options, that increasingly steer elective short-stay surgery away from acute hospitals [S5]. From its 2014 AltX listing until 2023 the group was dual-market. The profitable PresMed Australia subsidiary financed a loss-making South African build-out that never reached group-level profitability attributable to shareholders. After selling Australia to an ICG-led consortium and delisting, the business is a single-country, founder-controlled platform. It competes against the day-surgery arms of Netcare, Life Healthcare and Mediclinic and against independent chains such as Cure Day Hospitals. In February 2026 it announced that it had become the first hospital group in Africa certified to ISO 7101 [S36].


Company's own description (latest available filings and website)

In its last published interim report (H1 FY2023), the company described itself as an important participant in day surgery in South Africa and Australia. It said it had positioned itself within each market's healthcare system to meet growing demand for day procedures [S5 · H1 FY2023]. The current website states the aim of being the industry leader in day surgery through a network of day hospitals, with a focus on high-quality, cost-effective care [S37 · 2026]. It defines day hospitals as facilities performing short surgical and diagnostic procedures in a sterile environment on a same-day basis, and claims that more than 60% of surgical interventions can be done this way [S37].

Independent characterisation

Advanced Health is a facility operator, not a clinical practice. Revenue comes from patients, almost entirely funded by medical schemes and partly by private cash payers. It is billed as facility, theatre and accommodation fees, equipment and fixed fees, and drugs and gases dispensed during procedures [S4 · FY2022]. Surgeons and anaesthetists are independent practitioners who bill separately. The model depends on three relationships:

  1. Doctors. Surgeons choose where to operate. The group has historically offered participating doctors equity in each hospital's operating company while retaining majority control [S46]. The FY2022 and H1 FY2023 turnaround plans made selling shares in South African hospitals to specialists a formal strategic pillar [S4], [S5].

  2. Funders (medical schemes). Volume depends on network inclusion and tariff levels. Advanced Health is a member of the Day Hospital Association of South Africa (DHASA), which was authorised to negotiate tariffs collectively with schemes for 2023 [S4], [S5].

  3. Real estate. Facilities are mostly leased. On adopting IFRS 16 on 1 July 2019 the group recognised lease liabilities of R607.7m and right-of-use assets of R583.8m [S2 · FY2020]. This made lease finance costs the dominant fixed charge below EBITDA.

Business and revenue model mix

Revenue line (ZAR Mn)FY2018FY2019FY2020FY2021FY2022
Theatre, accommodation and facility fees (ZAR m)360.7407.3392.0574.3555.0
Equipment and fixed fees (ZAR m)6.618.821.412.813.9
Specialists (ZAR m)0.00.00.00.011.4
Drug revenue and gases (ZAR m)39.355.562.893.684.4
Total revenue (ZAR m)406.6481.7476.2680.7664.7

Sources: [S1 · FY2019 (FY2018–19)], [S2 · FY2020], [S4 · FY2022 (FY2021–22)]. "Specialists" revenue came from the consolidated Metwest entities in Australia from November 2021 [S4].

In FY2022, 90% of drug revenue came from South Africa, while 77% of facility-fee revenue came from Australia [S4 · FY2022]. This shows a structural difference: the South African hospitals depend far more on pharmaceutical dispensing.

Value-chain position, customers and end-markets

Value-chain position: a provider-level facility operator between funders (medical schemes and private payers) and independent specialists. It does not run medical schemes, own physician practices (except Metwest's ophthalmology practice in Australia before 2023) or manufacture anything.

Customer types: (i) patients, funded mainly by medical schemes; the website shows Discovery, GEMS, Bonitas, Polmed and Fedhealth logos [S35]; (ii) private cash patients, for whom the group points to third-party medical-loan providers [S35]; (iii) specialists as the de facto "channel"; (iv) institutional overflow in 2021, when theatres were made available to 1 Military Hospital [S21].

End-markets: South African private elective short-stay surgery (current). Australian private day surgery, mainly ophthalmology, ENT, pain management and oral-maxillofacial surgery, until 2023 [S8].

Strategy

Stated strategy (latest filings, FY2022 and H1 FY2023; paraphrased)

The last published strategy framed the South African turnaround around four pillars [S4], [S5]:

  1. Specialist partnership: selling equity in South African hospital operating companies to medical specialists.

  2. Funder engagement: using DHASA's authorisation to negotiate tariffs collectively with medical schemes (2023 tariffs) to secure reasonable increases and channel more volume to member hospitals.

  3. Marketing and doctor acquisition: engaging doctors, recruiting new specialists, and differentiating on service, including nursing care.

  4. Competitive pricing: for both private and low-income medical-scheme options, positioned for members downgrading to cheaper plans. Advanced Health says it accepts most low-cost options [S5].

Post-delisting statements (2026). The managing director described three core strategic pillars aimed at benefiting staff, patients and doctors, under the theme of affordable, quality care [S36]. Quality certification (ISO 7101, with three years of surveillance audits) is the most visible initiative [S36].

Strategic initiatives register (last 24 months and recent history)

DateInitiativeDetailSource
Not disclosed (website material from 2025)MFT Gqeberha integrationAdded the Eastern Cape's first private day hospital (3 theatres) to the network[S39]
Late 2025 – 9 Feb 2026ISO 7101 healthcare quality managementBSI audits of all hospitals and the central office; certification announced Feb 2026; ongoing compliance audits over three years[S36]
2025–2026Patient-experience transparencyPer-hospital patient-feedback scores published on the website (updated Oct 2026)[S35]
2025–2026Consumer funding channelPrivate-funding pathway via third-party lenders for procedures and shortfalls[S35]
2,023Delisting to cut compliance costsBoard said listing costs exceeded benefits; capital raising would be better served unlisted[S11]
2,023Balance-sheet restructuringPMA proceeds used first to settle outstanding credit facilities and fund South African working capital[S8], [S5]
2,021Cost-curtailment restructuringClosure of loss-making Soweto; sale of Vergelegen; strict South African cost measures[S18]

Medium-term targets and guidance

Not publicly disclosed. The company has never published quantitative medium-term financial targets. The last stated objective was qualitative: to become profitable and grow the footprint of independent, quality, cost-effective day hospitals [S5].

Sustainability and ESG commitments

Not publicly disclosed.

Products & Services

Service lines (billing categories)

Service lineDescriptionTarget customerPricing modelSource
Theatre / accommodation / facility feesUse of theatre, recovery and ward for same-day proceduresScheme-funded and cash patientsNegotiated scheme tariffs; co-payments per scheme rules; possible co-payment discounts for cash patients[S4], [S35]
Equipment and fixed feesEquipment use and fixed procedural charges (includes dental income and fee adjustments per FY2019 note)As abovePer procedure[S1], [S4]
Drugs and gasesPharmaceuticals and medical gases used in proceduresAs abovePer item dispensed[S4]
Specialist services (Australia only, FY2022)Ophthalmology practice revenue at MetwestAustralian private patientsPractice fees[S4]
Private funding facilitationReferral to third-party medical-finance providers for procedures, co-payments and shortfallsUninsured or under-insured patientsThird-party loan; terms not disclosed[S35]
Central-office management servicesManagement services provided to Summerhill Surgical Centre (third-party day hospital)Independent facility—[S38]

Clinical specialties offered (group level)

The company's descriptions and third-party profiles list: orthopaedics (knee, shoulder, elbow, hand, spine) including same-day hip and knee replacement (more than 300 performed); ophthalmology (cataract, corneal, laser, intra-ocular injection, vitrectomy, tear duct, pterygium; oculoplastics featured in 2026 content); ENT; gynaecology; urology; plastic, reconstructive and cosmetic surgery; dermatological excisions; dental and maxillofacial surgery; general surgery; and diagnostic endoscopy and colonoscopy [S35], [S37], [S49], [S36]. PMA in Australia specialised in ophthalmology, ENT, pain management and oral-maxillofacial surgery [S8].

Facility catalog — South Africa (current, per website, October 2026)

FacilityLocationProvinceKey specificationsOpening / joiningSource
Advanced De La VieBeatty Ave, Witbank (eMalahleni)MpumalangaNot disclosed. The De La Vie CGU's goodwill (R4.7m) was fully impaired in FY2020. The site appears linked to the former Witbank Day Clinic / Emalahleni Day Hospital, but the company has not confirmed thisEmalahleni reopened 2009; De La Vie date not disclosed[S35], [S2], [S37]
Advanced Durbanville3 Somerset Crescent, Durbanville, Cape TownWestern Cape—Planned for Q3 2015 (pre-opening guidance)[S35], [S46]
Advanced East Rand52 Olivia Rd, Eveleigh, BoksburgGautengNot disclosed. Classified within a held-for-sale group in FY2020 but still operating—[S35], [S2]
Advanced Harbour BayMain and Dido Valley Rd, Simon's TownWestern CapeCapex R8.3m in FY2020Opened 17 January 2020[S35], [S2]
Advanced Knysna4 Barracuda St, Fisher Haven, KnysnaWestern CapeNot disclosed; deferred tax asset derecognised FY2020—[S35], [S2]
Advanced MFT (Medical Forum Theatre)209 Cape Road, Mill Park, GqeberhaEastern Cape3 theatres, 15 beds, 7 ophthalmic recliner chairs; described as the Eastern Cape's first private day hospitalJoined post-delisting; date and terms not disclosed[S39]
Advanced MedgateKingfisher and Pheasant St, Helderkruin, RoodepoortGauteng—One of two South African facilities at the 2014 listing[S35], [S27]
Advanced Panorama55 Hennie Winterbach St, Panorama, Cape TownWestern Cape—Operational January 2016[S35], [S25]
Advanced Worcester43 Russell St, WorcesterWestern Cape——[S35]

Former South African facilities: Advanced Vergelegen Surgical Centre (Somerset West; business sold to Hibosys / Summerhill Surgical Centre in 2021) [S18]; Advanced Soweto Day Hospital (operations discontinued 2021; liquidated 11 August 2022) [S4].

Facility catalog — Australia (divested 2023)

FacilityLocationNotesSource
Chatswood Private HospitalChatswood, SydneyFlagship six-theatre day clinic opened January 2016; only Australian private hospital member of the World Association of Eye Hospitals[S25], [S1], [S4]
Epping Surgery CentreEpping, SydneyNew lease in FY2022 added R60.3m of right-of-use assets[S4]
Central Coast facilityCentral Coast, NSWNamed facility not disclosed in the filings retrieved[S33]
Hornsby facilityHornsby, SydneyOne-theatre ophthalmic day hospital acquisition agreed in principle (2017)[S24], [S33]
Metwest Surgical (Hereward) and Eye Centre (Kingham)Blacktown / Western Sydney19% (2019), later 38% (associate), then 57% (Nov 2021, controlled)[S1], [S4], [S33]
Devonport Eye Hospital and Clearvis (DEVOCLEA)Devonport, Tasmania20% (July 2021), later 40% associate[S22], [S4]
Sydney Pain Day SurgerySydneyRight-of-use asset of R12.5m recognised in H1 FY2023[S5]
Madison Day SurgerySydney (location not disclosed)100% acquired in FY2018[S1]
Coffs Harbour Day HospitalCoffs Harbour, NSWOne-theatre clinic; closed and sold 29 March 2019[S1]

PMA owned or co-owned ten operating facilities (day hospitals and consultation clinics) at the time of sale [S8].

Flagship differentiators claimed

  • Price: up to 30% cheaper than the same procedure at larger hospitals (company claim) [S35].

  • Quality: ISO 7101 certification across all hospitals and the central office, awarded by BSI and announced 9 February 2026 [S36].

  • Patient satisfaction: the website displays an average score of 97% or above from patient feedback [S35].

  • Australian training credentials (pre-2023): an in-house ophthalmic nurse programme, an ophthalmologist registrar training programme and University of Sydney teaching-hospital affiliation [S4].

Financial Narrative

Coverage: FY2018–FY2022 audited or reviewed annual figures. FY2023 annual results were not publicly disclosed; no FY2023 annual filing was located before the September 2023 delisting. FY2018 and FY2019 are pre-IFRS 16 and FY2020 onward are post-IFRS 16, so EBITDA, finance costs and debt are not like-for-like across that break.

Income statement

Sources: [S1 · FY2019 (FY2018–19)], [S2 · FY2020], [S4 · FY2022 (FY2021–22)]. Notes: FY2019 cost of sales and gross profit are as restated in FY2020 after the nursing-cost reclassification. FY2018 gross profit (R207.3m) is as originally presented and is not adjusted for that reclassification, so it is not strictly comparable. EBIT is analyst-derived as EBITDA − D&A − impairments, excluding investment income, associate income and fair-value gains. FY2022 pre-tax income includes a R17.7m Metwest fair-value gain and R9.4m of associate income. FY2021 attributable figures are as restated in FY2022.

Sources: [S1], [S2], [S4]. FY2021 EPS as restated in FY2022 (originally −5.21c basic and −3.89c headline) [S4]. A 20c clean-out dividend per share was paid on 27 September 2023 (FY2024), declared out of income reserves [S14], [S17].

Analyst-derived. Revenue CAGR FY2018–FY2022: 13.1% (R406.6m to R664.7m). In AUD-neutral terms Australian revenue grew from about AUD29.0m to AUD40.4m. Part of the FY2021 ZAR jump came from a weaker rand (average AUD/ZAR 11.49 in FY2021 against 10.49 in FY2020) [S2], [S4].

Income statement commentary.

FY2018–FY2019 (build-out drag): Revenue rose 18% in FY2019 on 21% more cases, with South Africa up 38% [S1]. Losses persisted because the eight South African hospitals commissioned in a short period took longer than expected to settle in. Management itself guided that new hospitals need a "settling-in period" of up to 36 months [S25], [S1].

FY2020 (IFRS 16 and COVID): Reported EBITDA tripled to R54.5m, but R46.6m of that was the IFRS 16 reclassification of rent. Excluding IFRS 16, EBITDA fell 55% to R7.9m because of the Q4 lockdown [S2]. The net loss reached R133.8m, driven by IFRS 16 interest (R51.4m), the derecognition of R21.6m of South African deferred tax assets and the De La Vie goodwill impairment [S2].

FY2021 (post-lockdown backlog): Revenue jumped 43% to R680.7m. Australia's EBITDA was R133.6m as deferred elective surgery flowed back, a surge the company later called non-recurring [S4]. The group made a small after-tax profit of R0.6m, but owners still lost R27.7m.

FY2022 (normalisation): Revenue eased 2% and EBITDA fell to R134.3m. Australia was hit by Delta- and Omicron-era throughput caps, and South Africa by lower revenue and load-shedding costs [S4]. Profit after tax of R13.4m relied on the R17.7m non-cash Metwest gain. Without it, the group would have reported a loss.

Balance sheet

Sources: [S1], [S2], [S4]; derived totals are analyst-derived. Lease liabilities for FY2018–FY2019 are finance-lease obligations only (pre-IFRS 16; operating-lease straight-lining liabilities of R24.5m and R28.1m are excluded). FY2020 total assets include R202.7m of disposal-group assets. FY2021 equity split is restated. Working capital includes disposal groups.

Balance-sheet commentary. Three features stand out. (1) IFRS 16 doubled the balance sheet in FY2020: lease liabilities went from R20.9m to R467.7m, which permanently raised reported leverage. (2) Attributable equity collapsed from R193.8m (FY2018) to R19.0m (FY2022) as accumulated losses reached R294.8m [S4], while NCI grew to R214.2m. Minorities therefore owned most of the book equity, mainly through PMA. (3) The book value understated the economic value of PMA. AVL's 56.44% stake was sold for about R522m [S8], against total group attributable equity of R19.0m at 30 June 2022. This gap underpins the board's statement that the shares traded at a discount to underlying net asset value [S11].

Cash flow

Sources: [S1], [S2], [S4]; FCF analyst-derived.

Source: [S4 · FY2022]; FCF after leases analyst-derived. For FY2020 the cash-flow statement combines lease interest with other finance costs (R41.5m) alongside R17.5m of lease capital repaid [S2], so a like-for-like figure cannot be isolated.

Cash-flow commentary. Under IFRS 16 rent moves into financing, so the improvement in operating cash flow from FY2020 is mostly presentational. On a lease-adjusted basis, group FCF was modest: about R27m in FY2021 and R23m in FY2022. That was smaller than dividends paid out to Australian minorities in FY2022 (R18.6m) plus South Africa's financing needs. Eenhede Konsultante filled the gap: R53.8m of new loans in FY2022 and R6.2m in H1 FY2023 [S4], [S5]. The cash-flow statements show no capital returned to AVL shareholders until the 2023 clean-out dividend.

Ratios

All analyst-derived from [S1], [S2], [S4]. ROIC assumes the 28% South African statutory rate. Working-capital days use closing balances, and payables include non-trade items, so the cycle is approximate. FY2021 DSO is inflated by a R15.2m Devonport deposit held in receivables [S4]. Company-reported current ratios, which exclude disposal groups, were 1.02 (FY2019), 0.80 (FY2020), 1.20 (FY2021) and 1.27 (FY2022) [S1], [S2], [S4]. The analyst figure for FY2022 (1.22) does not reconcile exactly to the company's 1.27.

Analyst-derived; FY2018 is not meaningful because EBITDA was negative.

Ratio commentary. Attributable ROE was deeply negative throughout. The FY2020 and FY2022 figures look extreme because attributable equity had shrunk to a very small base. The more informative signal is EBIT interest cover of 1.1–1.3x in the two best years (FY2021–FY2022), meaning almost all operating profit went to lenders and lessors before reaching any shareholder. The structurally negative cash conversion cycle (payables longer than receivables plus inventory) is typical of hospitals. In FY2022 the company also said South African trade creditors were rising because of cash-flow strain [S4], which suggests creditors were partly financing the business.

Going-concern history

Auditors Mazars issued unmodified review opinions with emphasis-of-matter paragraphs on going concern in FY2020 and FY2022 [S2], [S4]. Third-party coverage also reported auditor doubts [S9a]. In FY2022, South Africa's current liabilities exceeded its current assets by R40.9m [S4]. The board's stated mitigation was the sale of strategic investments, which became the PMA disposal [S4], [S8].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsServices

South Africa

Advanced Health South Africa (Pty) Ltd and its hospital operating companies (doctor co-owned)

Day-surgery facility fees, equipment fees, drugs and gases

Australia (to 2023)

PresMed Australia Pty Ltd and subsidiaries/associates: Chatswood Private Hospital, Epping Surgery Centre, Central Coast, Hornsby, Metwest (Blacktown / Western Sydney), Devonport (Tasmania, 40% associate), Sydney Pain Day Surgery, among others

Day-surgery facility fees; specialist ophthalmology consulting (Metwest)

Corporate

Advanced Health Limited (listed company)

Holding-company costs; borrowings from Eenhede Konsultante

Segment revenue (ZAR Mn)

Segment revenue (ZAR Mn)FY2018FY2019FY2020FY2021FY2022

South Africa (ZAR Mn)

117.4162.2177.0229.5219.1

Australia (ZAR Mn)

289.2319.4299.3451.2445.7

Group (ZAR Mn)

406.6481.7476.2680.7664.7

Segment revenue growth YoY (%)

Segment revenue growth YoY (%)FY2019FY2020FY2021FY2022

South Africa (%)

38.29.129.7-4.6

Australia (%)

10.5-6.350.8-1.2

Group (%)

18.5-1.142.9-2.3

Revenue contribution (% of group)

Revenue contribution (% of group)FY2018FY2019FY2020FY2021FY2022

South Africa (%)

28.933.737.233.733.0

Australia (%)

71.166.362.866.367.0

Segment profit/(loss) after tax (ZAR Mn)

Segment profit/(loss) after tax (ZAR Mn)FY2018FY2019FY2020FY2021FY2022

South Africa (ZAR Mn)

-42.8-46.0-132.4-47.7-41.0

Australia (ZAR Mn)

7.59.914.462.562.6

Corporate (ZAR Mn)

-1.0-1.9-15.8-14.3-8.2

Group (ZAR Mn)

-36.2-38.0-133.80.613.4

Segment EBITDA (ZAR Mn)

Segment EBITDA (ZAR Mn)FY2021FY2022

South Africa (ZAR Mn)

37.327.4

Australia (ZAR Mn)

133.6108.0

Corporate (ZAR Mn)

-8.3-1.0

Segment EBITDA margin (%)

Segment EBITDA margin (%)FY2021FY2022

South Africa (%)

16.312.5

Australia (%)

29.624.2

Results by Segment

Item (ZAR Mn)H1 FY2022H1 FY2023

Continuing revenue (South Africa)

103.9126.6

Continuing gross profit

45.359.8

Continuing EBITDA (incl. corporate)

11.913.7

South Africa segment EBITDA

15.117.3

Continuing finance costs

19.722.2

Loss from continuing operations

-21.9-23.1

Profit from discontinued operations (Australia)

22.723.6

Group profit after tax

0.80.4

Income statement (ZAR Mn)

Income statement (ZAR Mn)FY2018FY2019FY2020FY2021FY2022

Revenue (ZAR Mn)

406.6481.7476.2680.7664.7

Cost of sales (ZAR Mn)

199.3255.8261.6348.4344.9

Gross profit (ZAR Mn)

207.3225.9214.6332.3319.8

EBITDA as reported (ZAR Mn)

-0.117.654.5162.6134.3

Depreciation and amortisation (ZAR Mn)

32.534.571.566.871.6

Impairments (ZAR Mn)

0.00.04.79.94.8

Operating income, EBIT derived (ZAR Mn)

-32.6-16.9-21.785.957.9

Finance costs (ZAR Mn)

14.716.474.267.553.8

Pre-tax income, continuing (ZAR Mn)

-46.5-32.4-94.124.431.6

Tax charge, negative = credit (ZAR Mn)

-15.8-7.839.723.818.1

Net income, total group (ZAR Mn)

-36.2-38.0-133.80.613.4

Net income attributable to owners (ZAR Mn)

-39.6-44.7-147.1-27.7-20.1

Net income attributable to NCI (ZAR Mn)

3.36.713.328.333.6

Per-share data (ZAR cents)

Per-share data (ZAR cents)FY2018FY2019FY2020FY2021FY2022

Basic EPS, total (ZAR cents)

-14.12-15.51-51.08-8.14-4.04

Diluted EPS, total (ZAR cents)

-14.12-15.51-51.08-8.14-4.04

Headline EPS (ZAR cents)

-14.12-10.84-49.42-6.82-5.89

Dividend per share (ZAR cents)

00000

Weighted average shares (millions)

280.4288.0288.0340.5498.8

Margins (%)

Margins (%)FY2018FY2019FY2020FY2021FY2022

Gross margin (%)

51.046.945.148.848.1

EBITDA margin (%)

0.03.711.423.920.2

Operating (EBIT) margin (%)

-8.0-3.5-4.612.68.7

Net margin, total group (%)

-8.9-7.9-28.10.12.0

Net margin, attributable (%)

-9.7-9.3-30.9-4.1-3.0

Balance Sheet

Balance sheet (ZAR Mn, 30 June)FY2018FY2019FY2020FY2021FY2022

Total assets (ZAR Mn)

515.0531.21,078.3926.31,096.0

Cash and equivalents (ZAR Mn)

41.345.259.8107.2129.7

Borrowings excl. leases (ZAR Mn)

145.7200.2181.6192.6213.6

Lease liabilities (ZAR Mn)

38.220.9467.7431.9537.9

Bank overdraft (ZAR Mn)

0.011.33.111.47.7

Total debt incl. leases (ZAR Mn)

183.9232.4652.4635.9759.2

Short-term debt (ZAR Mn)

36.942.464.474.977.0

Long-term debt (ZAR Mn)

147.0189.9587.9561.0682.2

Net debt incl. leases (ZAR Mn)

142.6187.2592.6528.7629.5

Net debt excl. leases (ZAR Mn)

104.4166.3124.996.891.6

Equity attributable to owners (ZAR Mn)

193.8145.838.744.519.0

Non-controlling interest (ZAR Mn)

53.564.1115.6135.2214.2

Total equity (ZAR Mn)

247.3210.0154.4179.7233.2

Goodwill and intangibles (ZAR Mn)

63.760.448.837.8107.3

Working capital, total CA − CL (ZAR Mn)

-0.91.8-21.530.039.1

Cash flow (ZAR Mn)

Cash flow (ZAR Mn)FY2018FY2019FY2020FY2021FY2022

Cash generated from operations (ZAR Mn)

5.815.677.6111.8140.1

Net operating cash flow (ZAR Mn)

-13.2-5.758.7104.8105.2

Capex, PPE and intangibles (ZAR Mn)

55.817.518.712.325.0

Free cash flow, operating less capex (ZAR Mn)

-69.0-23.240.092.580.2

Dividends paid to NCI by subsidiaries (ZAR Mn)

6.08.310.210.718.6

Dividends paid to AVL shareholders (ZAR Mn)

00000

Share buybacks (ZAR Mn)

00000

Lease cash outflows, post-IFRS 16 (ZAR Mn)

Lease cash outflows, post-IFRS 16 (ZAR Mn)FY2021FY2022

Lease capital repayments (ZAR Mn)

16.020.7

Lease interest paid (ZAR Mn)

49.236.9

FCF after lease payments (ZAR Mn)

27.322.6

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatiosFY2018FY2019FY2020FY2021FY2022

ROE, attributable earnings / closing attributable equity (%)

-20.4-30.6-380.1-62.2-105.8

ROE, total profit / closing total equity (%)

-14.7-18.1-86.70.35.8

ROA, total profit / closing total assets (%)

-7.0-7.2-12.40.11.2

ROIC, EBIT × (1 − 28%) / (equity + net debt incl. leases) (%)

-6.0-3.1-2.18.74.8

Current ratio, analyst incl. disposal groups (x)

0.991.020.941.161.22

Debt / equity, incl. leases (x)

0.741.114.233.543.26

Interest coverage, EBIT / finance costs (x)

-2.22-1.03-0.291.271.08

EBITDA / finance costs (x)

-0.011.070.732.412.50

Asset turnover, revenue / closing total assets (x)

0.790.910.440.730.61

Days sales outstanding (days)

30.028.626.737.130.0

Days inventory outstanding (days)

25.623.021.220.021.7

Days payables outstanding (days)

84.178.186.662.074.7

Cash conversion cycle (days)

-28.5-26.5-38.7-4.9-23.0

Net debt / EBITDA, incl. leases (x)

Net debt / EBITDA, incl. leases (x)FY2019FY2020FY2021FY2022

Net debt / EBITDA (x)

10.610.93.34.7

Geographic revenue (ZAR Mn)

Geographic revenue (ZAR Mn)FY2018FY2019FY2020FY2021FY2022

South Africa (ZAR Mn)

117.4162.2177.0229.5219.1

Australia (ZAR Mn)

289.2319.4299.3451.2445.7

Australia revenue in AUD at average rates (AUD Mn)

Australia revenue in AUD at average rates (AUD Mn)FY2018FY2019FY2020FY2021FY2022

Australia (AUD Mn)

29.031.528.539.340.4

Revenue by type and geography, FY2022 (ZAR Mn)

Revenue by type and geography, FY2022 (ZAR Mn)South AfricaAustraliaTotal

Facility fees

129.9425.1555.0

Equipment and fixed fees

13.30.613.9

Specialists

0.011.411.4

Drugs and gases

75.98.584.4

Total

219.1445.7664.7

Share Price History

DatePrice / value (ZAR cents)ContextSource

Apr 2014

100

AltX listing issue price

[S31]

Aug 2017

130

Rights offer subscription price

[S26]

18 Aug 2017

106

Closing price amid an increased-loss trading update

[S28]

Late 2020

18 (low)

Trough

[S31]

Apr 2021

24

Rights offer price

[S19], [S20]

Nov 2022

25

Before the PMA deal

[S31]

Jun 2023

80

Scheme consideration

[S11]

Sep 2023

80 + 20

Scheme plus clean-out dividend = 100c total exit

[S14], [S31]

Share Count (millions) and Per-Share Data

Capital dataFY2018FY2019FY2020FY2021FY2022

Shares in issue, year-end (millions)

288.0288.0288.0498.8498.8

NAV per share, total equity incl. NCI (ZAR cents)

85.972.953.636.046.7

NAV per share, attributable to owners (ZAR cents)

67.350.613.48.93.8

Dividend per share (ZAR cents)

00000

Analyst Conclusions

Management guidance

There is no quantitative guidance. The last formal statement (April 2023) expected the remaining South African business to become profitable and to grow a footprint of independent, quality, cost-effective day hospitals [S5]. 2026 communications emphasise quality (ISO 7101) and three pillars (staff, patients, doctors) [S36].

Consensus

Not available (unlisted; no sell-side coverage).

Bull case

  1. Lower fixed charges: PMA proceeds of about R522m were earmarked to settle credit facilities [S8]. Holding-company finance costs (R7.9m in H1 FY2023 [S5]) and EK interest could fall sharply, letting South African EBITDA (R17.3m in H1 FY2023) convert to profit.

  2. Structural tailwinds: scheme steering, co-payments on acute use and member down-trading favour low-price day facilities [S5]. Day surgery was only 12–15% of South African private surgery in 2018, against much higher shares abroad [S29].

  3. Differentiation and reach: ISO 7101 [S36], same-day joint replacement capability [S35] and Eastern Cape entry through MFT [S39] widen the procedure pool and strengthen the case for network inclusion.

Bear case

  1. History of losses: South Africa lost R41–132m a year over five years and never reported an after-tax profit [S1]–[S4]. Even the FY2021 COVID backlog year produced a R47.7m South African loss.

  2. Competitive pressure: Cure Day Hospitals (14 sites, including a 2026 opening in the same Gqeberha market) is out-scaling Advanced Health [S43]. The acute groups operate their own day facilities and are investing heavily from strong cash flows (Netcare capex R1.63bn in FY2025) [S40], [S42].

  3. Opacity and funding concentration: no public financials since H1 FY2023, a single controlling funder, and leases that still weigh heavily on the remaining business, leave outsiders unable to verify any turnaround.

Catalysts and monitorables (next 12 months)

  • Any published annual financial statements (CIPC filings, PAIA disclosures) showing post-2023 profitability.

  • Constitutional Court rulings on the NHI process and any subsequent promulgation [S44].

  • 2027 medical-scheme tariff outcomes negotiated through DHASA.

  • Network changes: new openings, acquisitions or doctor-equity sales.

  • ISO 7101 surveillance audits [S36].

  • MFT's competitive position after Cure's Gqeberha opening [S43].

  • Funder solvency events, given the 2026 curatorship that affected Life Healthcare [S42].

Analyst verdict

Advanced Health's listed life (2014–2023) is best read as an expensive experiment in building an independent South African day-hospital network inside a structure that could not fund it. The Australian subsidiary was the economic engine. It generated R62.5–62.6m of after-tax profit a year by FY2021–FY2022 [S4] and was finally monetised for about AUD45m [S8]. The South African build-out absorbed that value: South Africa lost money every year on record, the group carried going-concern emphasis paragraphs, and attributable book equity fell from R193.8m to R19.0m between FY2018 and FY2022 [S1], [S4]. Public shareholders who bought at the 100c listing price left with exactly 100c nine years later [S31].

The fundamental thesis behind the business was not wrong. Day surgery is cheaper, schemes increasingly favour it, and South Africa remains under-penetrated compared with developed markets [S29], [S5]. The failure was one of capital structure and scale. Leases and related-party debt consumed most of the EBITDA, and a sub-national footprint limited bargaining power with funders.

Today's Advanced Health is a smaller, single-country, founder-controlled operator of nine hospitals. It has better quality credentials (ISO 7101) and, assuming the PMA proceeds retired debt as stated, probably a lighter balance sheet. It also faces a better-scaled independent rival in Cure Day Hospitals and well-capitalised acute incumbents. Because the company publishes no financials, any claim that the turnaround has succeeded cannot be verified.

Verdict: for counterparties such as funders, suppliers, landlords and potential acquirers, Advanced Health should be treated as a credible but sub-scale niche operator with an unproven profit model. Diligence should focus on post-2023 audited accounts, the remaining lease commitments, surgeon retention and any continuing financial support from Eenhede Konsultante. For investors, there is no public instrument. The most plausible future events are consolidation (Advanced Health as either acquirer or target) or selective doctor-equity raises, rather than a return to the public market.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / notesEducation / ageSource

Carl Alfred Grillenberger

Founder; non-executive chairman (from 28 Aug 2019); previously CEO

Founder; CEO at listing (2014) and in 2018

Founded PresMed (South Africa) in 1982 and PresMed Australia in 1997; associated with controlling shareholder Eenhede Konsultante

—

[S27], [S29], [S33], [S1], [S30]

Gerhard (Gerhardus Jacobus) van Emmenis

Chief Executive Officer

From 1 Aug 2019; quoted as CEO in Aug 2023. Current status not confirmed by 2026 sources

——

[S1], [S31]

D. (Bibi) Goss-Ross

Managing Director, Advanced Health Group (title used Feb 2026); previously MD South Africa and executive director

Alternate director to 1 Dec 2021, then director

Led the company through ISO 7101 certification

—

[S4], [S5], [S36]

M. Stoltz

Interim CFO

From 1 Apr 2023

——

[S5]

Sinenhlanhla Chonco CA(SA)

CFO (former)

1 Feb 2020 – 31 Mar 2023

—

CA(SA)

[S2], [S5]

Marna Castelyn

Acting CFO (former)

1 Nov 2019 – Jan 2020

——

[S2]

Carel Petrus Snyman CA(SA)

CFO (former)

To 31 Oct 2019

—

CA(SA)

[S1]

Marc C. Resnik

MD / COO Australia (former executive director)

To the PMA sale (2023)

Exercised options for 76,672 PMA shares (4.13%) through Kinser Investments in FY2022

Australian

[S4]

Sr Anina de Bruyn

Group Clinical and Quality Manager

Current (2026)

Led the ISO 7101 project

—

[S36]

M. Janse van Rensburg

Company Secretary

FY2019–FY2023

——

[S1], [S5]

“—” = not publicly disclosed.

Board of Directors

DirectorRoleIndependence / notesSource

C.A. Grillenberger

Chairman, non-executive

Not independent (controlling-shareholder associate)

[S5]

F.A. van Hoogstraten

Lead independent non-executive director; chairman until Aug 2019

Independent

[S5], [S1]

P.J. (Phil) Jaffe

Non-executive director

Independent; Independent Board member for the 2023 scheme; Australian

[S5], [S11]

Dr W.T. (Tommy) Mthembu

Non-executive director

Independent; Independent Board member for the 2023 scheme

[S5], [S11]

Y.J. (Cobus) Visser

Non-executive director (previously alternate)

Independent; Independent Board member for the 2023 scheme

[S5], [S11]

C.J.P.G. van Zyl

Non-executive director

Independence not stated

[S5]

Dr K.E. (Kgao) Legodi

Non-executive director (from 27 Nov 2019)

Independence not stated

[S2], [S5]

G.J. van Emmenis

CEO, executive director

Executive

[S5]

M.C. Resnik

MD Australia, executive director

Executive

[S5]

D. Goss-Ross

MD South Africa, executive director

Executive

[S5]

S. Chonco

CFO, executive director (to 31 Mar 2023)

Executive

[S5]

Dr J. Oelofse

Former non-executive director

Term ended 12 Nov 2021

[S4]

Major Shareholders

ShareholderShares% of issued

Eenhede Konsultante Eiendoms Beperk (offeror)

287,495,27657.64

Pres Medical Witbank (Pty) Ltd (excluded shareholder)

53,190,44010.66

John Biccard (irrevocable undertaking)

12,831,3842.57

Rendement (Pty) Ltd (irrevocable undertaking)

12,800,0002.57

Carl Grillenberger Family Trust (excluded shareholder)

10,420,5082.09

Bremer Investments (Pty) Ltd (irrevocable undertaking)

6,497,5001.30

VC Family Trust (excluded shareholder)

3,661,2590.73

Fiona Biccard (irrevocable undertaking)

836,3910.17

Offeror plus excluded shareholders (concert group)

354,767,48671.13

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with Advanced HealthScale / financialsSource

Netcare Ltd

Listed national acute group with day-surgery and eye facilities (e.g. Netcare Optiklin Eye Hospital)

Elective surgery volumes; network inclusion

FY2025 revenue R26,344m; normalised EBITDA R4,912m (18.6%)

[S40], [S95a]

Life Healthcare Group

Listed national acute group with day hospitals (e.g. Life Brooklyn Day Hospital)

Same

FY2025 acute revenue R21.3bn (like-for-like); group normalised EBITDA R3.8bn

[S41], [S91a]

Mediclinic Southern Africa

Acute group with day clinics (e.g. Bloemfontein, Limpopo, Nelspruit day clinics)

Same

—

[S91a]

Cure Day Hospitals Holdings

Independent day-hospital chain (founded 2007 by doctors)

Most direct business-model competitor; overlaps in Gqeberha

14 hospitals as of June 2026; financials not publicly disclosed

[S43], [S47]

Intercare

Day hospitals (e.g. Irene)

Gauteng day surgery

—

[S91a]

Melomed Hospital Holdings

Private hospital group, Western Cape

Western Cape elective surgery

—

[S48]

National Hospital Network (NHN)

Network of independent hospitals

Funder contracting alternative for independents

—

[S48]

Edge Day Hospital

Independent day hospital

Day surgery

—

[S48]

Bay Eye Hospital

Independent ophthalmic hospital

Ophthalmology

—

[S48]

Independent day hospitals (e.g. Medgate's network peers, Mercidoc, Birchmed, Karibu, Groenkloof)

Single-site independents

Local competition for surgeons

—

[S97a]

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricAdvanced Health (FY2022, group)Advanced Health (FY2022, South Africa only)Netcare (FY2025)Life Healthcare (FY2025)Cure Day Hospitals

Revenue

R664.7m

R219.1m

R26,344m

Acute R21.3bn (like-for-like)

—

Revenue growth

-2.3%-4.6%4.5%

Group 6.0%

—

EBITDA margin

20.2%12.5%

18.6% (normalised)

——

Facilities

9 SA + 10 AU (FY2022)

9–10

National

National

14 (Jun 2026)

“—” = not publicly disclosed.

Company Snapshot

$40.6M

Revenue

1997

Founded

SWOT Analysis

Strengths

  • Positive South African unit economics at EBITDA level: South African EBITDA of R37.3m (FY2021) and R27.4m (FY2022) at margins of 16.3% and 12.5% [S4].
  • Improving South African gross margin: from 44% to 47% in H1 FY2023 [S5].
  • Revenue momentum before delisting: South African continuing revenue up 22% in H1 FY2023 [S5].
  • Quality credential: ISO 7101 certification across all hospitals and the central office (Feb 2026) [S36].
  • Committed controlling shareholder: Eenhede Konsultante underwrote rights offers in 2017 and 2021, lent R53.8m in FY2022 and funded the 2023 buyout [S26], [S19], [S4], [S11].
  • Cleaner balance sheet after the PMA sale: proceeds of about R522m were applied first to settling credit facilities [S8].

Weaknesses

  • Persistent South African net losses: R42.8m to R132.4m a year, FY2018–FY2022 [S1], [S2], [S4].
  • Thin coverage of fixed charges: EBIT interest cover of 1.27x (FY2021) and 1.08x (FY2022) at group level; South African interest of R29.5m against EBITDA of R27.4m in FY2022 [S4].
  • Repeated going-concern emphasis of matter (FY2020, FY2022) [S2], [S4].
  • Facility failures: Coffs Harbour (closed after about a year), Soweto (liquidated) and Vergelegen (sold) [S1], [S4], [S18].
  • Disclosure-quality issues: an FY2021 NCI restatement, an IFRS 16 opening-balance correction and an inconsistent re-presentation of FY2022 in the H1 FY2023 report [S4], [S2], [S5].
  • Concentrated, related-party funding: EK loan interest of R9.4m in FY2022 [S4].

Opportunities

  • Scheme steering and co-payments for acute-hospital use of day procedures [S5].
  • Consumer down-trading to low-cost options that Advanced accepts [S5].
  • Wider procedure scope: same-day joint replacement (more than 300 done) [S35].
  • Eastern Cape entry through MFT (3 theatres, 15 beds) [S39].
  • Management-services income from third-party facilities such as Summerhill [S38].
  • Doctor-equity sales to raise capital and secure volumes [S4], [S5].

Threats

  • Cure Day Hospitals expanding to 14 hospitals, including a new Gqeberha facility in June 2026 [S43].
  • Acute groups' own day clinics and network contracting [S91a].
  • Funder failure risk: a scheme placed under curatorship cost Life Healthcare R130m of revenue in H1 FY2026 [S42].
  • NHI legal and policy uncertainty, with 14 or more court cases [S44].
  • Interest-rate exposure: prime-linked EK debt raised finance costs in H1 FY2023 [S5].
  • Grid instability (load-shedding) adding cost and reducing efficiency [S4].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (assets dated May 2025)Advanced MFT (Gqeberha) appears on the group website with facility imagery [S39]Network expansion into the Eastern Cape (deal terms not disclosed)
2025 (document dated Oct 2025)PAIA manual published for AMFT [S39]Formal legal-entity compliance for MFT under Advanced Health
Late 2025 (pre-festive season)BSI audits of all hospitals and the central office for ISO 7101 [S36]Prerequisite for certification
24 Nov 2025Netcare FY2025: revenue up 4.5% to R26.3bn; normalised EBITDA margin 18.6% [S40]Listed acute-hospital competitor gaining margin
27 Nov 2025Life Healthcare FY2025: acute revenue R21.3bn (like-for-like); group normalised EBITDA R3.8bn [S41]Competitor stability; complementary services expanding
Feb 2026President pauses promulgation of NHI Act provisions pending Constitutional Court rulings [S44], [S52]Delays the structural funding shift; reduces near-term disruption to medical-scheme-funded volumes
9 Feb 2026Advanced Health announces ISO 7101 certification, described as the first in Africa [S36]Quality differentiation for funders and doctors
Mar 2026Health Minister reports 14 legal cases against the NHI, with possible delays of 15–20 years [S44]Prolongs uncertainty for private providers
2026New corporate logo (2026 assets on website) [S35]Brand refresh
31 Mar 2026Clinical content published (paediatric dental) [S36]Specialty marketing for dental day surgery
5–7 May 2026Constitutional Court hears challenges to the NHI public-participation process [S44]–
21 May 2026Netcare H1 FY2026 trading statement: EPS and HEPS up 18–23% [S42]Strong competitor earnings momentum
28 May 2026Life Healthcare H1 FY2026: revenue up 2.4% to R12.42bn; a funder under curatorship cut revenue by R130m [S42]Shows funder credit risk affecting hospital revenue
28 Jun 2026Cure Day Hospitals opens a R100m day hospital in Newton Park, Gqeberha (its 14th nationally) [S43]Direct new competition for Advanced MFT in the same metro
23 Jul 2026Self-care campaign content [S36]Patient engagement
6 Aug 2026President reaffirms NHI foundational work [S44]Continued policy direction
14 Aug 2026Surgeon-authored breast-cancer content (Dr Fatima Hoosain, general surgeon) [S36]Doctor engagement and specialty positioning
24 Aug 2026Oculoplastics content [S36]Ophthalmic positioning
17 Sep 2026World Patient Safety Day content [S36]Reinforces the ISO 7101 and safety message
21 Sep 2026Women's health (bladder) content [S36]Gynaecology and urology positioning
Oct 2026Per-hospital patient-feedback scores refreshed on the website [S35]Transparency on service quality

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from ZAR 406.6 Mn in FY2018 to ZAR 664.7 Mn in FY2022.
Advanced Health Limited — Income Statement: Revenue & Gross Profit
Series (ZAR Mn)FY2018FY2019FY2020FY2021FY2022
Revenue406.6481.7476.2680.7664.7
Cost of sales199.3255.8261.6348.4344.9
Gross profit207.3225.9214.6332.3319.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1AVL reviewed condensed consolidated AFS, FY2019 — 29 Aug 2019 (senspdf.jse.co.za)
  2. S2AVL reviewed condensed consolidated AFS, FY2020 — 25 Sep 2020 (senspdf.jse.co.za)
  3. S3AVL interim results, H1 FY2021 — 26 Feb 2021 (senspdf.jse.co.za)
  4. S4AVL reviewed condensed consolidated AFS, FY2022 — 8 Sep 2022 (senspdf.jse.co.za)
  5. S5AVL interim results, H1 FY2023 — 3 Apr 2023 (senspdf.jse.co.za)
  6. S6AVL interim short-form, H1 FY2022 — 25 Feb 2022 (senspdf.jse.co.za)
  7. S7Change statement and AGM notice (FY2021) — 15 Oct 2021 (senspdf.jse.co.za)
  8. S8Detailed terms: disposal of 56.44% of PMA — 23 Dec 2022 (senspdf.jse.co.za)
  9. S9Firm intention: PMA disposal — 30 Jan 2023 (senspdf.jse.co.za)
  10. S9aSimply Wall St AVL page (headline on auditor doubts) — n.d. (simplywall.st)
  11. S10PMA disposal general meeting results — 28 Mar 2023 (senspdf.jse.co.za)
  12. S11Firm intention: scheme of arrangement — 28 Jun 2023 (senspdf.jse.co.za)
  13. S12Scheme circular posting and salient dates — 26 Jul 2023 (senspdf.jse.co.za)
  14. S13Scheme meeting results — 25 Aug 2023 (senspdf.jse.co.za)
  15. S14Clean-out dividend vote and declaration — 28 Aug 2023 (senspdf.jse.co.za)
  16. S15Finalisation announcement — 11 Sep 2023 (senspdf.jse.co.za)
  17. S16FTSE/JSE index deletion notice — 13 Sep 2023 (clientportal.jse.co.za)
  18. S17ShareData: AVL (suspended) pages — Sep 2023 · sharedata.co.za
  19. S18Renewal of cautionary (Vergelegen, restructuring, rights offer) — 2 Feb 2021 (senspdf.jse.co.za)
  20. S19Rights offer declaration — 15 Mar 2021 (senspdf.jse.co.za)
  21. S19aAVL interim H1 FY2022 (scheme co-payment commentary) — Feb 2022 (senspdf.jse.co.za)
  22. S20Rights offer results — 6 Apr 2021 (senspdf.jse.co.za)
  23. S21Voluntary update — 26 Mar 2021 (senspdf.jse.co.za)
  24. S22DEVOCLEA update — 8 Jul 2021 (senspdf.jse.co.za)
  25. S23DEVOCLEA cautionary withdrawal — 10 Dec 2021 (senspdf.jse.co.za)
  26. S24Trading statement (ShareData) — 8 Jun 2017 (sharedata.co.za)
  27. S25Initial trading statement (ShareData) — 1 Jun 2016 (sharedata.co.za)
  28. S26Rights offer results 2017 (ShareData) — 7 Aug 2017 (sharedata.co.za)
  29. S27Business Report: "Demand high for Advanced Health on AltX" — 24 Apr 2014 (businessreport.co.za)
  30. S28Business Day: growth plans under pressure — 21 Aug 2017 (businessday.co.za)
  31. S29Business Day: slow growth halts plans — 31 Aug 2018 (businesslive.co.za)
  32. S30Business Day: Advanced Health to delist — 28 Jun 2023 (businessday.co.za)
  33. S31Business Day: clean-out dividend — 16 Aug 2023 (businessday.co.za)
  34. S32Gilbert + Tobin: PMA sale to ICG — 2023 (gtlaw.com.au)
  35. S33The Lawyer Magazine (AU): PMA sale and PresMed history — 2023 (thelawyermag.com)
  36. S34Oaklins deal pages (PMA sale; 2021 rights offer) — 2021–2023 · oaklins.com
  37. S35Advanced Health website, home page — Oct 2026 (advancedhealth.co.za)
  38. S36Advanced Health news: ISO 7101 certification (plus news listing) — 9 Feb 2026 (advancedhealth.co.za)
  39. S37Advanced Health: About Us / history — Oct 2026 (advancedhealth.co.za)
  40. S38Advanced Health: Central Office — Oct 2026 (advancedhealth.co.za)
  41. S39Advanced Health: Advanced MFT — Oct 2026 (advancedhealth.co.za)
  42. S40Netcare FY2025 results — 24 Nov 2025 (netcare.co.za)
  43. S41Life Healthcare FY2025 media release — 27 Nov 2025 (lifehealthcare.co.za)
  44. S42Daily Investor: Netcare H1 FY2026 trading statement; Life H1 FY2026 — May 2026 · dailyinvestor.com
  45. S43The Herald: Cure Day Hospitals opens in Gqeberha — 28 Jun 2026 (theherald.co.za)
  46. S44BusinessTech: NHI status (Mar and Aug 2026) — 2026 · businesstech.co.za · businesstech.co.za
  47. S45Profile's Stock Exchange Handbook 2020 / 2021 — 2020–2021 (profile.co.za)
  48. S46Momentum provider news: expansion plans and doctor-equity model — c. 2014–2015 (provider.momentum.co.za)
  49. S47Cure Day Hospitals profile (12 hospitals, pre-2025) — c. 2024 (topbusinesswomen.co.za)
  50. S48ResearchAndMarkets: Healthcare Sector in South Africa 2025 (company list) — 29 Dec 2025 (businesswire.com)
  51. S49Investing.com company profile — n.d. (m.uk.investing.com)
  52. S51AVL interim results, H1 FY2020 — Feb 2020 (senspdf.jse.co.za)
  53. S52Bhekisisa / TimesLive: NHI litigation — Mar 2026 (bhekisisa.org)
  54. S91aLA Health Focus network list (day clinics of acute groups and independents) — 2025 (lahealth.co.za)
  55. S95aUCT medical-scheme day-surgery network list — n.d. (hr.uct.ac.za)
  56. S97aLA Health Focus network (independent day hospitals incl. Medgate, Emalahleni) — n.d. (bemas.co.za)
  57. S100aBusiness Report: Netcare FY2025 (surgical cases >70% of revenue) — 24 Nov 2025 (businessreport.co.za)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.